Home > > > > > Report Detail

Global (United States, European Union and China) Hepatocellular Carcinoma Drugs Market Research Report 2019-2025

Publisher Name :
Date: 16-Aug-2019
No. of pages: 118
Inquire Before Buying

HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.

The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2017. The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury. The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market. However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market.

In 2019, the market size of Hepatocellular Carcinoma Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Hepatocellular Carcinoma Drugs.

This report studies the global market size of Hepatocellular Carcinoma Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

This study presents the Hepatocellular Carcinoma Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:

- Bayer

- Eli Lilly

- Johnson and Johnson

- Pfizer

- Bristol-Myers Squibb

- Celgene

- F. Hoffmann-la Roche

- Gilead

- GlaxoSmithKline

- Merck

- Novartis

Market Segment by Product Type

- Brachytherapy

- Chemotherapy

- Local Ablation Therapy

Market Segment by Application

- Hospitals

- Clinics

- Cancer Rehabilitation Centers

Key Regions split in this report: breakdown data for each region.

- United States

- China

- European Union

- Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:

- To analyze and research the Hepatocellular Carcinoma Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

- To present the key Hepatocellular Carcinoma Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.

- To split the breakdown data by regions, type, companies and applications

- To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.

- To identify significant trends, drivers, influence factors in global and regions

- To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Hepatocellular Carcinoma Drugs are as follows:

- History Year: 2014-2018

- Base Year: 2018

- Estimated Year: 2019

- Forecast Year 2019 to 2025

Global (United States, European Union and China) Hepatocellular Carcinoma Drugs Market Research Report 2019-2025

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Hepatocellular Carcinoma Drugs Market Size Growth Rate by Type (2019-2025)
1.3.2 Brachytherapy
1.3.3 Chemotherapy
1.3.4 Local Ablation Therapy
1.4 Market Segment by Application
1.4.1 Global Hepatocellular Carcinoma Drugs Market Share by Application (2019-2025)
1.4.2 Hospitals
1.4.3 Clinics
1.4.4 Cancer Rehabilitation Centers
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hepatocellular Carcinoma Drugs Market Size
2.1.1 Global Hepatocellular Carcinoma Drugs Revenue 2014-2025
2.1.2 Global Hepatocellular Carcinoma Drugs Sales 2014-2025
2.2 Hepatocellular Carcinoma Drugs Growth Rate by Regions
2.2.1 Global Hepatocellular Carcinoma Drugs Sales by Regions 2014-2019
2.2.2 Global Hepatocellular Carcinoma Drugs Revenue by Regions 2014-2019
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
3 Market Share by Manufacturers
3.1 Hepatocellular Carcinoma Drugs Sales by Manufacturers
3.1.1 Hepatocellular Carcinoma Drugs Sales by Manufacturers 2014-2019
3.1.2 Hepatocellular Carcinoma Drugs Sales Market Share by Manufacturers 2014-2019
3.2 Revenue by Manufacturers
3.2.1 Hepatocellular Carcinoma Drugs Revenue by Manufacturers (2014-2019)
3.2.2 Hepatocellular Carcinoma Drugs Revenue Share by Manufacturers (2014-2019)
3.2.3 Global Hepatocellular Carcinoma Drugs Market Concentration Ratio (CR5 and HHI)
3.3 Hepatocellular Carcinoma Drugs Price by Manufacturers
3.4 Key Manufacturers Hepatocellular Carcinoma Drugs Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Hepatocellular Carcinoma Drugs Market
3.6 Key Manufacturers Hepatocellular Carcinoma Drugs Product Offered
3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 Brachytherapy Sales and Revenue (2014-2019)
4.1.2 Chemotherapy Sales and Revenue (2014-2019)
4.1.3 Local Ablation Therapy Sales and Revenue (2014-2019)
4.2 Global Hepatocellular Carcinoma Drugs Sales Market Share by Type
4.3 Global Hepatocellular Carcinoma Drugs Revenue Market Share by Type
4.4 Hepatocellular Carcinoma Drugs Price by Type
5 Market Size by Application
5.1 Overview
5.2 Global Hepatocellular Carcinoma Drugs Sales by Application
6 United States
6.1 United States Hepatocellular Carcinoma Drugs Breakdown Data by Company
6.2 United States Hepatocellular Carcinoma Drugs Breakdown Data by Type
6.3 United States Hepatocellular Carcinoma Drugs Breakdown Data by Application
7 European Union
7.1 European Union Hepatocellular Carcinoma Drugs Breakdown Data by Company
7.2 European Union Hepatocellular Carcinoma Drugs Breakdown Data by Type
7.3 European Union Hepatocellular Carcinoma Drugs Breakdown Data by Application
8 China
8.1 China Hepatocellular Carcinoma Drugs Breakdown Data by Company
8.2 China Hepatocellular Carcinoma Drugs Breakdown Data by Type
8.3 China Hepatocellular Carcinoma Drugs Breakdown Data by Application
9 Rest of World
9.1 Rest of World Hepatocellular Carcinoma Drugs Breakdown Data by Company
9.2 Rest of World Hepatocellular Carcinoma Drugs Breakdown Data by Type
9.3 Rest of World Hepatocellular Carcinoma Drugs Breakdown Data by Application
9.4 Rest of World Hepatocellular Carcinoma Drugs Breakdown Data by Countries
9.4.1 Rest of World Hepatocellular Carcinoma Drugs Sales by Countries
9.4.2 Rest of World Hepatocellular Carcinoma Drugs Revenue by Countries
9.4.3 Japan
9.4.4 Korea
9.4.5 India
9.4.6 Southeast Asia
10 Company Profiles
10.1 Bayer
10.1.1 Bayer Company Details
10.1.2 Company Description and Business Overview
10.1.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
10.1.4 Hepatocellular Carcinoma Drugs Product Introduction
10.1.5 Bayer Recent Development
10.2 Eli Lilly
10.2.1 Eli Lilly Company Details
10.2.2 Company Description and Business Overview
10.2.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
10.2.4 Hepatocellular Carcinoma Drugs Product Introduction
10.2.5 Eli Lilly Recent Development
10.3 Johnson and Johnson
10.3.1 Johnson and Johnson Company Details
10.3.2 Company Description and Business Overview
10.3.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
10.3.4 Hepatocellular Carcinoma Drugs Product Introduction
10.3.5 Johnson and Johnson Recent Development
10.4 Pfizer
10.4.1 Pfizer Company Details
10.4.2 Company Description and Business Overview
10.4.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
10.4.4 Hepatocellular Carcinoma Drugs Product Introduction
10.4.5 Pfizer Recent Development
10.5 Bristol-Myers Squibb
10.5.1 Bristol-Myers Squibb Company Details
10.5.2 Company Description and Business Overview
10.5.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
10.5.4 Hepatocellular Carcinoma Drugs Product Introduction
10.5.5 Bristol-Myers Squibb Recent Development
10.6 Celgene
10.6.1 Celgene Company Details
10.6.2 Company Description and Business Overview
10.6.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
10.6.4 Hepatocellular Carcinoma Drugs Product Introduction
10.6.5 Celgene Recent Development
10.7 F. Hoffmann-la Roche
10.7.1 F. Hoffmann-la Roche Company Details
10.7.2 Company Description and Business Overview
10.7.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
10.7.4 Hepatocellular Carcinoma Drugs Product Introduction
10.7.5 F. Hoffmann-la Roche Recent Development
10.8 Gilead
10.8.1 Gilead Company Details
10.8.2 Company Description and Business Overview
10.8.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
10.8.4 Hepatocellular Carcinoma Drugs Product Introduction
10.8.5 Gilead Recent Development
10.9 GlaxoSmithKline
10.9.1 GlaxoSmithKline Company Details
10.9.2 Company Description and Business Overview
10.9.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
10.9.4 Hepatocellular Carcinoma Drugs Product Introduction
10.9.5 GlaxoSmithKline Recent Development
10.10 Merck
10.10.1 Merck Company Details
10.10.2 Company Description and Business Overview
10.10.3 Sales, Revenue and Market Share of Hepatocellular Carcinoma Drugs
10.10.4 Hepatocellular Carcinoma Drugs Product Introduction
10.10.5 Merck Recent Development
10.11 Novartis
11 Value Chain and Sales Channels Analysis
11.1 Value Chain Analysis
11.2 Sales Channels Analysis
11.2.1 Hepatocellular Carcinoma Drugs Sales Channels
11.2.2 Hepatocellular Carcinoma Drugs Distributors
11.3 Hepatocellular Carcinoma Drugs Customers
12 Market Forecast
12.1 Global Hepatocellular Carcinoma Drugs Sales and Revenue Forecast 2019-2025
12.2 Global Hepatocellular Carcinoma Drugs Sales Forecast by Type
12.3 Global Hepatocellular Carcinoma Drugs Sales Forecast by Application
12.4 Hepatocellular Carcinoma Drugs Forecast by Regions
12.4.1 Global Hepatocellular Carcinoma Drugs Sales Forecast by Regions 2019-2025
12.4.2 Global Hepatocellular Carcinoma Drugs Revenue Forecast by Regions 2019-2025
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
12.8.1 Japan
12.8.2 Korea
12.8.3 India
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables and Figures
Figure Hepatocellular Carcinoma Drugs Product Picture
Table Hepatocellular Carcinoma Drugs Key Market Segments
Table Major Manufacturers Hepatocellular Carcinoma Drugs Covered in This Report
Table Global Hepatocellular Carcinoma Drugs Market Size Growth Rate by Type 2019-2025 (K MT) & (Million US$)
Figure Global Hepatocellular Carcinoma Drugs Sales Market Shar by Type 2014-2025
Figure Brachytherapy Figures
Table Major Manufacturers of Brachytherapy
Figure Chemotherapy Figures
Table Major Manufacturers of Chemotherapy
Figure Local Ablation Therapy Figures
Table Major Manufacturers of Local Ablation Therapy
Table Global Hepatocellular Carcinoma Drugs Market Share by Application 2019-2025 (K MT)
Figure Hospitals Use Case
Figure Clinics Use Case
Figure Cancer Rehabilitation Centers Use Case
Figure Hepatocellular Carcinoma Drugs Report Years Considered
Figure Global Hepatocellular Carcinoma Drugs Market Size 2014-2025 (Million US$)
Figure Global Hepatocellular Carcinoma Drugs Sales 2014-2019 (K MT)
Table Global Hepatocellular Carcinoma Drugs Market Size by Regions 2014-2019 (K MT) & (Million US$)
Table Global Hepatocellular Carcinoma Drugs Sales by Regions 2014-2019 (K MT)
Table Global Hepatocellular Carcinoma Drugs Sales Market Share by Regions 2014-2019
Figure Global Hepatocellular Carcinoma Drugs Sales Market Share by Regions 2014-2019
Figure Global Hepatocellular Carcinoma Drugs Sales Market Share by Regions in 2019
Table Global Hepatocellular Carcinoma Drugs Revenue by Regions 2014-2019 (Million US$)
Table Global Hepatocellular Carcinoma Drugs Revenue Market Share by Regions 2014-2019
Figure Global Hepatocellular Carcinoma Drugs Revenue Market Share by Regions 2014-2019
Figure Global Hepatocellular Carcinoma Drugs Revenue Market Share by Regions in 2019
Table Market Top Trends
Table Global Hepatocellular Carcinoma Drugs Sales by Manufacturers (2014-2019) (K MT)
Table Global Hepatocellular Carcinoma Drugs Sales Share by Manufacturers (2014-2019)
Figure Global Hepatocellular Carcinoma Drugs Sales Share by Manufacturers in 2019
Table Hepatocellular Carcinoma Drugs Revenue by Manufacturers (2014-2019) (Million USD)
Table Hepatocellular Carcinoma Drugs Revenue Share by Manufacturers (2014-2019)
Figure Hepatocellular Carcinoma Drugs Value Share by Manufacturers in 2019
Table Global Hepatocellular Carcinoma Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Key Manufacturers Hepatocellular Carcinoma Drugs Price (2014-2019) (USD/MT)
Table Key Manufacturers Hepatocellular Carcinoma Drugs Plants/Factories Distribution
Table Key Manufacturers Hepatocellular Carcinoma Drugs Area Served
Table Date of Key Manufacturers Enter into Hepatocellular Carcinoma Drugs Market
Table Key Manufacturers Hepatocellular Carcinoma Drugs Product Type
Table Mergers & Acquisitions, Expansion Plans
Table Global Brachytherapy Sales and Revenue (2014-2019) (K MT) & (Million US$)
Table Global Chemotherapy Sales and Revenue (2014-2019) (K MT) & (Million US$)
Table Global Local Ablation Therapy Sales and Revenue (2014-2019) (K MT) & (Million US$)
Table Global Hepatocellular Carcinoma Drugs Sales by Type (2014-2019) (K MT)
Table Global Hepatocellular Carcinoma Drugs Sales Share by Type (2014-2019)
Figure Global Hepatocellular Carcinoma Drugs Sales Market Share by Type (2014-2019)
Figure Global Hepatocellular Carcinoma Drugs Sales Market Share by Type in 2018
Table Global Hepatocellular Carcinoma Drugs Revenue by Type (2014-2019) (Million US$)
Table Global Hepatocellular Carcinoma Drugs Revenue Share by Type (2014-2019)
Figure Global Hepatocellular Carcinoma Drugs Revenue Market Share by Type (2014-2019)
Figure Global Hepatocellular Carcinoma Drugs Revenue Market Share by Type in 2018
Table Hepatocellular Carcinoma Drugs Price by Type 2014-2019 (USD/MT)
Table Global Hepatocellular Carcinoma Drugs Sales by Application (2014-2019) (K MT)
Table Global Hepatocellular Carcinoma Drugs Sales Share by Application (2014-2019)
Figure Global Sales Hepatocellular Carcinoma Drugs Market Share by Application (2014-2019)
Figure Global Sales Hepatocellular Carcinoma Drugs Market Share by Application (2014-2019)
Figure United States Hepatocellular Carcinoma Drugs Sales Growth Rate 2014-2019 (K MT)
Figure United States Hepatocellular Carcinoma Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table United States Hepatocellular Carcinoma Drugs Sales by Company (2014-2019) (K MT)
Table United States Hepatocellular Carcinoma Drugs Sales Market Share by Company (2014-2019)
Figure United States Hepatocellular Carcinoma Drugs Sales Market Share by Company in 2019
Table United States Hepatocellular Carcinoma Drugs Sales by Type (2014-2019) (K MT)
Table United States Hepatocellular Carcinoma Drugs Sales Market Share by Type (2014-2019)
Figure United States Hepatocellular Carcinoma Drugs Market Share by Type in 2019
Table United States Hepatocellular Carcinoma Drugs Sales by Application (2014-2019) (K MT)
Table United States Hepatocellular Carcinoma Drugs Sales Market Share by Application (2014-2019)
Figure United States Hepatocellular Carcinoma Drugs Market Share by Application in 2019
Figure European Union Hepatocellular Carcinoma Drugs Sales Growth Rate 2014-2019 (K MT)
Figure European Union Hepatocellular Carcinoma Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table European Union Hepatocellular Carcinoma Drugs Sales by Company (2014-2019) (K MT)
Table European Union Hepatocellular Carcinoma Drugs Sales Market Share by Company (2014-2019)
Figure European Union Hepatocellular Carcinoma Drugs Sales Market Share by Company in 2019
Table European Union Hepatocellular Carcinoma Drugs Sales by Type (2014-2019) (K MT)
Table European Union Hepatocellular Carcinoma Drugs Sales Market Share by Type (2014-2019)
Figure 2018 European Union Hepatocellular Carcinoma Drugs Market Share by Type
Table European Union Hepatocellular Carcinoma Drugs Sales by Application (2014-2019) (K MT)
Table European Union Hepatocellular Carcinoma Drugs Sales Market Share by Application (2014-2019)
Figure 2018 European Union Hepatocellular Carcinoma Drugs Market Share by Application
Figure China Hepatocellular Carcinoma Drugs Sales Growth Rate 2014-2019 (K MT)
Figure China Hepatocellular Carcinoma Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table China Hepatocellular Carcinoma Drugs Sales by Company (2014-2019) (K MT)
Table China Hepatocellular Carcinoma Drugs Sales Market Share by Company (2014-2019)
Figure China Hepatocellular Carcinoma Drugs Sales Market Share by Company in 2019
Table China Hepatocellular Carcinoma Drugs Sales by Type (2014-2019) (K MT)
Table China Hepatocellular Carcinoma Drugs Sales Market Share by Type (2014-2019)
Figure China Hepatocellular Carcinoma Drugs Market Share by Type in 2019
Table China Hepatocellular Carcinoma Drugs Sales by Application (2014-2019) (K MT)
Table China Hepatocellular Carcinoma Drugs Sales Market Share by Application (2014-2019)
Figure China Hepatocellular Carcinoma Drugs Market Share by Application in 2019
Figure Rest of World Hepatocellular Carcinoma Drugs Sales Growth Rate 2014-2019 (K MT)
Figure Rest of World Hepatocellular Carcinoma Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table Rest of World Hepatocellular Carcinoma Drugs Sales by Company (2014-2019) (K MT)
Table Rest of World Hepatocellular Carcinoma Drugs Sales Market Share by Company (2014-2019)
Figure Rest of World Hepatocellular Carcinoma Drugs Sales Market Share by Company in 2019
Table Rest of World Hepatocellular Carcinoma Drugs Sales by Type (2014-2019) (K MT)
Table Rest of World Hepatocellular Carcinoma Drugs Sales Market Share by Type (2014-2019)
Figure Rest of World Hepatocellular Carcinoma Drugs Market Share by Type in 2019
Table Rest of World Hepatocellular Carcinoma Drugs Sales by Application (2014-2019) (K MT)
Table Rest of World Hepatocellular Carcinoma Drugs Sales Market Share by Application (2014-2019)
Figure Rest of World Hepatocellular Carcinoma Drugs Market Share by Application in 2019
Table Rest of World Hepatocellular Carcinoma Drugs Sales by Countries (2014-2019) (K MT)
Table Rest of World Hepatocellular Carcinoma Drugs Sales Market Share by Countries (2014-2019)
Figure Rest of World Hepatocellular Carcinoma Drugs Sales Market Share by Countries in 2019
Table Rest of World Hepatocellular Carcinoma Drugs Revenue by Countries (2014-2019) (Million US$)
Table Rest of World Hepatocellular Carcinoma Drugs Revenue Market Share by Countries (2014-2019)
Figure Rest of World Hepatocellular Carcinoma Drugs Revenue Market Share by Countries in 2019
Figure Japan Hepatocellular Carcinoma Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Japan Hepatocellular Carcinoma Drugs Revenue Growth Rate (2014-2019) (K MT)
Figure Korea Hepatocellular Carcinoma Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Korea Hepatocellular Carcinoma Drugs Revenue Growth Rate (2014-2019) (K MT)
Figure India Hepatocellular Carcinoma Drugs Sales Growth Rate (2014-2019) (K MT)
Figure India Hepatocellular Carcinoma Drugs Revenue Growth Rate (2014-2019) (K MT)
Figure Southeast Asia Hepatocellular Carcinoma Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Southeast Asia Hepatocellular Carcinoma Drugs Revenue Growth Rate (2014-2019) (K MT)
Table Bayer Company Details
Table Bayer Description and Business Overview
Table Bayer Hepatocellular Carcinoma Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Bayer Hepatocellular Carcinoma Drugs Sales Growth Rate (2014-2019)
Table Bayer Hepatocellular Carcinoma Drugs Sales Market Share in Global Market
Table Bayer Recent Development
Table Eli Lilly Company Details
Table Eli Lilly Description and Business Overview
Table Eli Lilly Hepatocellular Carcinoma Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Eli Lilly Hepatocellular Carcinoma Drugs Sales Growth Rate (2014-2019)
Table Eli Lilly Hepatocellular Carcinoma Drugs Sales Market Share in Global Market
Table Eli Lilly Recent Development
Table Johnson and Johnson Company Details
Table Johnson and Johnson Description and Business Overview
Table Johnson and Johnson Hepatocellular Carcinoma Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Johnson and Johnson Hepatocellular Carcinoma Drugs Sales Growth Rate (2014-2019)
Table Johnson and Johnson Hepatocellular Carcinoma Drugs Sales Market Share in Global Market
Table Johnson and Johnson Recent Development
Table Pfizer Company Details
Table Pfizer Description and Business Overview
Table Pfizer Hepatocellular Carcinoma Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Pfizer Hepatocellular Carcinoma Drugs Sales Growth Rate (2014-2019)
Table Pfizer Hepatocellular Carcinoma Drugs Sales Market Share in Global Market
Table Pfizer Recent Development
Table Bristol-Myers Squibb Company Details
Table Bristol-Myers Squibb Description and Business Overview
Table Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Sales Growth Rate (2014-2019)
Table Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Sales Market Share in Global Market
Table Bristol-Myers Squibb Recent Development
Table Celgene Company Details
Table Celgene Description and Business Overview
Table Celgene Hepatocellular Carcinoma Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Celgene Hepatocellular Carcinoma Drugs Sales Growth Rate (2014-2019)
Table Celgene Hepatocellular Carcinoma Drugs Sales Market Share in Global Market
Table Celgene Recent Development
Table F. Hoffmann-la Roche Company Details
Table F. Hoffmann-la Roche Description and Business Overview
Table F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Sales Growth Rate (2014-2019)
Table F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Sales Market Share in Global Market
Table F. Hoffmann-la Roche Recent Development
Table Gilead Company Details
Table Gilead Description and Business Overview
Table Gilead Hepatocellular Carcinoma Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Gilead Hepatocellular Carcinoma Drugs Sales Growth Rate (2014-2019)
Table Gilead Hepatocellular Carcinoma Drugs Sales Market Share in Global Market
Table Gilead Recent Development
Table GlaxoSmithKline Company Details
Table GlaxoSmithKline Description and Business Overview
Table GlaxoSmithKline Hepatocellular Carcinoma Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table GlaxoSmithKline Hepatocellular Carcinoma Drugs Sales Growth Rate (2014-2019)
Table GlaxoSmithKline Hepatocellular Carcinoma Drugs Sales Market Share in Global Market
Table GlaxoSmithKline Recent Development
Table Merck Company Details
Table Merck Description and Business Overview
Table Merck Hepatocellular Carcinoma Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Merck Hepatocellular Carcinoma Drugs Sales Growth Rate (2014-2019)
Table Merck Hepatocellular Carcinoma Drugs Sales Market Share in Global Market
Table Merck Recent Development
Table Novartis Company Details
Figure Hepatocellular Carcinoma Drugs Value Chain
Table Hepatocellular Carcinoma Drugs Distributors List
Table Hepatocellular Carcinoma Drugs Customers List
Table Global Hepatocellular Carcinoma Drugs Sales Forecast 2019-2025 (K MT) & (Million US$)
Figure Global Hepatocellular Carcinoma Drugs Sales Forecast 2019-2025 (K MT)
Figure Global Hepatocellular Carcinoma Drugs Revenue Forecast 2019-2025 (Million US$)
Table Global Hepatocellular Carcinoma Drugs Sales Forecast by Type 2019-2025 (K MT)
Figure Global Hepatocellular Carcinoma Drugs Sales Forecast by Type 2019-2025 (K MT)
Figure Global Hepatocellular Carcinoma Drugs Sales Market Share Forecast by Type 2019-2025
Table Global Hepatocellular Carcinoma Drugs Sales Forecast by Application 2019-2025 (K MT)
Figure Global Hepatocellular Carcinoma Drugs Sales Forecast by Application 2019-2025 (K MT)
Figure Global Hepatocellular Carcinoma Drugs Sales Market Share Forecast by Application 2019-2025
Table Global Hepatocellular Carcinoma Drugs Sales Forecast by Regions 2019-2025 (K MT)
Figure Global Hepatocellular Carcinoma Drugs Sales Forecast by Regions 2019-2025 (K MT)
Figure Global Hepatocellular Carcinoma Drugs Sales Market Share Forecast by Regions 2019-2025
Table Global Hepatocellular Carcinoma Drugs Revenue Forecast by Regions 2019-2025 (K MT)
Figure Global Hepatocellular Carcinoma Drugs Revenue Forecast by Regions 2019-2025 (K MT)
Figure Global Hepatocellular Carcinoma Drugs Revenue Market Share Forecast by Regions 2019-2025
Figure United States Hepatocellular Carcinoma Drugs Sales Forecast 2019-2025 (K MT)
Figure United States Hepatocellular Carcinoma Drugs Revenue Forecast 2019-2025 (Million US$)
Figure European Union Hepatocellular Carcinoma Drugs Sales Forecast 2019-2025 (K MT)
Figure European Union Hepatocellular Carcinoma Drugs Revenue Forecast 2019-2025 (Million US$)
Figure China Hepatocellular Carcinoma Drugs Sales Forecast 2019-2025 (K MT)
Figure China Hepatocellular Carcinoma Drugs Revenue Forecast 2019-2025 (Million US$)
Figure Japan Hepatocellular Carcinoma Drugs Sales Forecast 2019-2025 (K MT)
Figure Japan Hepatocellular Carcinoma Drugs Revenue Forecast 2019-2025 (Million US$)
Figure Korea Hepatocellular Carcinoma Drugs Sales Forecast 2019-2025 (K MT)
Figure Korea Hepatocellular Carcinoma Drugs Revenue Forecast 2019-2025 (Million US$)
Figure India Hepatocellular Carcinoma Drugs Sales Forecast 2019-2025 (K MT)
Figure India Hepatocellular Carcinoma Drugs Revenue Forecast 2019-2025 (Million US$)
Figure Southeast Asia Hepatocellular Carcinoma Drugs Sales Forecast 2019-2025 (K MT)
Figure Southeast Asia Hepatocellular Carcinoma Drugs Revenue Forecast 2019-2025 (Million US$)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
  • Global 5-Fluorouracil Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 76
    The global 5-Fluorouracil market was valued at US$ 283 million in 2023 and is anticipated to reach US$ 487.9 million by 2030, witnessing a CAGR of 4.3% during The forecast period 2024-2030. North American market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by ......
  • Global Carboplatin Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79
    The global Carboplatin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % d......
  • Global Neutropenia Drugs Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 96
    The global Neutropenia Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated to increa......
  • Global Small Molecule Cancer Drug Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Small Molecule Cancer Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated ......
  • Global Capecitabine Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 80
    Capecitabine is an orally-administered chemotherapeutic agent used in The treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in The tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blo......
  • Global Oxaliplatin Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 104
    Oxaliplatin is a platinum-based anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy The third stage colon cancer after resecting primary tumor completely. In this report, only The finished drug is covered, exclude API. The global Oxaliplatin market was valued at US$ 897.5 million in 2023 and is anticipated to reach US$ 1641.5 million by 2030, witnessing a CAGR of 8.9% duri......
  • Global Cancer Treatment Drugs Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 158
    According to our LPI (LP Information) latest study, the global Cancer Treatment Drugs market size was valued at US$ 174990 million in 2023. With growing demand in downstream market, the Cancer Treatment Drugs is forecast to a readjusted size of US$ 322540 million by 2030 with a CAGR of 9.1% during review period. The research report highlights the growth potential of the global Cancer Treatment Drugs market. Cancer Treatment Drugs are expected to show stable growth in the future market. H......
  • Global Capecitabine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 93
    According to our LPI (LP Information) latest study, the global Capecitabine market size was valued at US$ 1003.9 million in 2023. With growing demand in downstream market, the Capecitabine is forecast to a readjusted size of US$ 975.1 million by 2030 with a CAGR of -0.4% during review period. The research report highlights the growth potential of the global Capecitabine market. Capecitabine are expected to show stable growth in the future market. However, product differentiation, reducin......
  • Global Methotrexate Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 95
    According to our LPI (LP Information) latest study, the global Methotrexate market size was valued at US$ 506 million in 2023. With growing demand in downstream market, the Methotrexate is forecast to a readjusted size of US$ 613.9 million by 2030 with a CAGR of 2.8% during review period. The research report highlights the growth potential of the global Methotrexate market. Methotrexate are expected to show stable growth in the future market. However, product differentiation, reducing co......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs